Attached files
| file | filename |
|---|---|
| EX-99.3 - Vyant Bio, Inc. | ex99-3.htm |
| EX-99.2 - Vyant Bio, Inc. | ex99-2.htm |
| EX-99.1 - Vyant Bio, Inc. | ex99-1.htm |
| EX-23.1 - Vyant Bio, Inc. | ex23-1.htm |
| EX-10.7 - Vyant Bio, Inc. | ex10-7.htm |
| EX-10.6 - Vyant Bio, Inc. | ex10-6.htm |
| EX-10.5 - Vyant Bio, Inc. | ex10-5.htm |
| EX-10.4 - Vyant Bio, Inc. | ex10-4.htm |
| EX-10.3 - Vyant Bio, Inc. | ex10-3.htm |
| EX-10.2 - Vyant Bio, Inc. | ex10-2.htm |
| EX-10.1 - Vyant Bio, Inc. | ex10-1.htm |
| EX-4.1 - Vyant Bio, Inc. | ex4-1.htm |
| EX-3.1 - Vyant Bio, Inc. | ex3-1.htm |
| 8-K - Vyant Bio, Inc. | form8-k.htm |
Exhibit 16.1
April 5, 2021
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Commissioners:
We have read the statements made by Vyant Bio, Inc. (formerly Cancer Genetics, Inc.) under Item 4.01 of its Form 8-K dated April 5, 2021. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Vyant Bio, Inc. (formerly Cancer Genetics, Inc.) contained therein.
Very truly yours,
/s/ Marcum LLP
Marcum LLP